搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
ENDPOINTS NEWS
11 小时
FDA won't take action against GLP-1 compounders as it rethinks tirzepatide shortage
The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...
FiercePharma
4 天
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
2 天
on MSN
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
4 天
on MSN
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
3 天
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
scrippsnews on MSN
3 天
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
Health on MSN
2 天
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
11 小时
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
2 天
on MSN
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
FiercePharma
10 天
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
4 天
on MSN
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
Yahoo
4 天
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The surprise move is a major victory for compounding pharmacists and patients who were furious with the FDA after its announcement on Oct. 2 that the tirzepatide shortage was resolved. Shortages ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈